Related Experiment Videos
Differences that matter: major cytotoxic T cell-stimulating minor histocompatibility antigens
S Malarkannan1, T Horng, P Eden
1Department of Molecular and Cell Biology, University of California, Berkeley 94720, USA.
Immunity
|October 6, 2000
Summary
Researchers identified a new BALB.B antigen, H28, presenting the ILENFPRL peptide. This, along with H60, explains the C57BI/6 anti-BALB.B immune response, driven by differential gene expression.
Area of Science:
- Immunology
- Genetics
- Molecular Biology
Background:
- Histocompatibility antigens are crucial in tissue graft rejection.
- Cytotoxic T cells (CTLs) target these antigens, leading to immune responses.
- Despite MHC matching, unknown antigens contribute to graft rejection.
Purpose of the Study:
- To identify novel histocompatibility antigens involved in anti-graft immune responses.
- To characterize the genetic basis and peptide presentation of these antigens.
Main Methods:
- cDNA isolation of a novel BALB.B antigen gene.
- Identification of the H28 locus on chromosome 3.
- Analysis of peptide processing and presentation by MHC molecules.
- Quantification of CTL responses against specific antigen-MHC complexes.
Main Results:
- A novel BALB.B antigen gene was isolated, defining the H28 locus.
- The H28 locus yields the naturally processed ILENFPRL (IFL8) peptide.
- IFL8 peptide is presented by Kb MHC to C57BI/6 CTLs.
- IFL8/Kb and H60/Kb complexes constitute a major fraction of the anti-BALB.B immune response.
- Differential transcription and expression in antigen-presenting cells explain immunodominance.
Conclusions:
- The H28 antigen and its presented IFL8 peptide are key targets in the C57BI/6 anti-BALB.B immune response.
- Differential gene expression and APC presentation contribute to the immunodominance of H28 and H60 antigens.